B. Braun09.06.16
The Renal Therapies Division of B. Braun Medical Inc. is launching xevonta, a next-generation dialyzer for the U.S. market, after recently receiving U.S. Food and Drug Administration 510(k) clearance. A dialyzer is a dialysis filter and is often referred to as an “artificial kidney.” Its function is to remove the wastes and excess fluid from the blood when a patient’s kidneys can no longer perform the task.
“Our new dialyzer’s advanced membrane technology was designed to improve clearance performance by removing more toxins from a patient’s blood,” said Samuel Amory, vice president, Renal Therapies Division, at B. Braun Medical.
B. Braun has enhanced the technology of formulating the amembris fibers in xevonta by designing the filtration membrane to filter out the smaller toxin molecules in the patient’s blood, like urea and creatinine, while maintaining most of the larger blood components, like albumin and beta-2 microglobulin molecules, that are vital to a patient’s health.
Available this month, xevonta will be offered in a broad range of sizes to accommodate different patient requirements.
B. Braun's Dialog+ Hemodialysis System incorporates state-of-the art technology in dialysis. In addition, B. Braun’s dialysis product line offers a wide array of disposable products that allow healthcare professionals to tailor treatments for their patients.
As a manufacturer and distributor of hemodialysis equipment and related disposables, including the Diacap @ Polysulfone dialyzers and Medisystems’ Streamline Bloodlines, the Renal Therapies Division of B. Braun develops products for hemodialysis and continuous renal replacement therapy. B. Braun Medical Inc. develops, manufactures, and markets infusion therapy and pain management products and services to the healthcare industry. B. Braun Medical is part of the B. Braun Group of Companies in the United States, which is headquartered in Bethlehem, Pa., and includes B. Braun Interventional Systems, Aesculap, and CAPS.
“Our new dialyzer’s advanced membrane technology was designed to improve clearance performance by removing more toxins from a patient’s blood,” said Samuel Amory, vice president, Renal Therapies Division, at B. Braun Medical.
B. Braun has enhanced the technology of formulating the amembris fibers in xevonta by designing the filtration membrane to filter out the smaller toxin molecules in the patient’s blood, like urea and creatinine, while maintaining most of the larger blood components, like albumin and beta-2 microglobulin molecules, that are vital to a patient’s health.
Available this month, xevonta will be offered in a broad range of sizes to accommodate different patient requirements.
B. Braun's Dialog+ Hemodialysis System incorporates state-of-the art technology in dialysis. In addition, B. Braun’s dialysis product line offers a wide array of disposable products that allow healthcare professionals to tailor treatments for their patients.
As a manufacturer and distributor of hemodialysis equipment and related disposables, including the Diacap @ Polysulfone dialyzers and Medisystems’ Streamline Bloodlines, the Renal Therapies Division of B. Braun develops products for hemodialysis and continuous renal replacement therapy. B. Braun Medical Inc. develops, manufactures, and markets infusion therapy and pain management products and services to the healthcare industry. B. Braun Medical is part of the B. Braun Group of Companies in the United States, which is headquartered in Bethlehem, Pa., and includes B. Braun Interventional Systems, Aesculap, and CAPS.